Ionis licences new antisense drug for kidney disease to AstraZeneca
Ionis Pharmaceuticals announced it has licensed IONIS-AZ5-2.5Rx to AstraZeneca. IONIS-AZ5-2.5Rx is a Generation 2.5 antisense drug, discovered by Ionis and designed to inhibit an undisclosed target to treat a genetically associated form of kidney disease. February 20, 2018